Clinically, high APE1 expression has been documented in prostate, lung, ovarian, colorectal, pancreatic, melanoma, head and neck, and other cancers, and generally correlates with advanced stage, chemoresistance, and poor survival, yet the underlying causes of APE1 overexpression in tumors remain unclear [124, 128–138]. Here, APEX1 is linked to cancer.